Equities analysts expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) will announce sales of $9.78 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aquestive Therapeutics’ earnings, with estimates ranging from $9.30 million to $10.26 million. Aquestive Therapeutics reported sales of $11.12 million during the same quarter last year, which indicates a negative year-over-year growth rate of 12.1%. The business is expected to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Aquestive Therapeutics will report full year sales of $51.13 million for the current financial year, with estimates ranging from $46.50 million to $55.76 million. For the next year, analysts anticipate that the company will post sales of $73.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Aquestive Therapeutics.
Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The firm had revenue of $11.08 million for the quarter, compared to analyst estimates of $9.81 million. During the same period in the previous year, the business posted ($0.60) EPS.
Shares of NASDAQ AQST traded down $0.13 during midday trading on Wednesday, reaching $2.09. 364,805 shares of the stock were exchanged, compared to its average volume of 292,472. The company has a market capitalization of $86.67 million, a P/E ratio of -1.14 and a beta of 3.30. Aquestive Therapeutics has a 52-week low of $2.02 and a 52-week high of $6.40. The stock has a 50 day moving average price of $2.60 and a 200-day moving average price of $3.86.
Hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA lifted its position in Aquestive Therapeutics by 13,532.5% during the fourth quarter. BNP Paribas Arbitrage SA now owns 15,950 shares of the company’s stock valued at $62,000 after buying an additional 15,833 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $110,000. Cubist Systematic Strategies LLC acquired a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $116,000. Bank of America Corp DE lifted its position in Aquestive Therapeutics by 381.3% during the fourth quarter. Bank of America Corp DE now owns 36,371 shares of the company’s stock valued at $141,000 after buying an additional 28,814 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in Aquestive Therapeutics by 29.9% during the third quarter. Two Sigma Advisers LP now owns 47,300 shares of the company’s stock valued at $206,000 after buying an additional 10,900 shares in the last quarter. 39.17% of the stock is currently owned by hedge funds and other institutional investors.
About Aquestive Therapeutics (Get Rating)
Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
- Get a free copy of the StockNews.com research report on Aquestive Therapeutics (AQST)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.